Antiandrogen therapy in hidradenitis suppurativa: finasteride for females

Summary Background Given its widely accepted efficacy, androgen blockade therapy for hidradenitis suppurativa (HS) has become a standard of care. Although much less frequently used than spironolactone, a small number of HS studies have reported finasteride as an alternative treatment for women. In t...

Full description

Saved in:
Bibliographic Details
Published in:Clinical and experimental dermatology 2022-01, Vol.47 (1), p.86-92
Main Authors: Babbush, K. M., Andriano, T. M., Cohen, S. R.
Format: Article
Language:English
Subjects:
Adult
Androgen Antagonists - therapeutic use
Androgens
Breast
Female
Females
Finasteride - therapeutic use
Hidradenitis Suppurativa - drug therapy
Humans
Intolerance
Menstruation
Middle Aged
Nausea
Patients
Quality of life
Retrospective Studies
Treatment Outcome
Young Adult
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Background Given its widely accepted efficacy, androgen blockade therapy for hidradenitis suppurativa (HS) has become a standard of care. Although much less frequently used than spironolactone, a small number of HS studies have reported finasteride as an alternative treatment for women. In this study, we describe the response to and perception of finasteride therapy in a diverse cohort of women with HS. Aim To describe finasteride therapy in a diverse cohort of female patients with HS. Methods We conducted an institutional review board‐approved retrospective chart review and telephone survey of 20 female patients aged ≥ 18 years with a diagnosis of HS. Finasteride was prescribed by a single provider at a specialized HS centre. Results The mean age of the patients was 34.3 ± 13.5 years. Finasteride was initiated predominantly because of one or more contraindications or poor responsiveness to spironolactone. Most patients interviewed (90%; n = 18) were willing to take finasteride again or continue with therapy if indicated. Of the 20 patients, 10 (50%) reported overall satisfaction with finasteride, while 7 (35%) were neutral and 3 (15%) were dissatisfied. No patient reported worsening disease activity while on finasteride and only one (5%) reported decreased quality of life. When asked about adverse effects of finasteride, 80% (n = 16) reported none, while 20% (n = 4) experienced ≥ 1 of the following: headache, nausea, menstrual irregularities, breast tenderness or reduced libido/sexual function. Conclusions Our study suggests that androgen blockade therapy with finasteride is a safe and effective alternative for female patients with HS who have contraindication(s) or intolerance to spironolactone.
ISSN:0307-6938
1365-2230
DOI:10.1111/ced.14847